Compare Cintas Corporation (CTAS) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs BIO-TECHNE Corp — how do they compare? Cintas Corporation trades at $187.92 (market cap $73.53B), while BIO-TECHNE Corp trades at $71.23 (market cap $11.12B). The key difference: Cintas Corporation is far larger — about 6.6× BIO-TECHNE Corp's market cap, and Cintas Corporation pays the higher dividend (0.98%). Which is the better fit depends on your goals.
| CTAS | TECH | |
|---|---|---|
Market Cap | $73.53B | $11.12B |
Sector | Industrials | Health |
52-Week High | $226.27 | $71.38 |
52-Week Low | $163.55 | $43.31 |
Enterprise Value | $76.26B | $11.20B |
Dividend Yield | 0.98% | 0.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
